Metastatic Cervical Cancer (DBCOND0036674)

Identifiers

Synonyms

Metastatic Cervical Cancers / Cervical Cancer Metastatic

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Bevacizumab	A monoclonal anti-vascular endothelial growth factor antibody used in combination with antineoplastic agents for the treatment of many types of cancer.	Vascular endothelial growth factor A, long formtarget Complement C1q subcomponent subunit Atarget Complement C1q subcomponent subunit Btarget Complement C1q subcomponent subunit Ctarget Low affinity immunoglobulin gamma Fc region receptor III-Atarget Low affinity immunoglobulin gamma Fc region receptor II-atarget Low affinity immunoglobulin gamma Fc region receptor II-btarget Low affinity immunoglobulin gamma Fc region receptor II-ctarget High affinity immunoglobulin gamma Fc receptor Itarget
Cemiplimab	A programmed death receptor-1 blocking antibody used to treat cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer.	Programmed cell death protein 1target
Irinotecan	A topoisomerase inhibitor used to treat metastatic carcinoma of the colon or rectum and pancreatic adenocarcinoma.	DNA topoisomerase I, mitochondrialtarget DNA topoisomerase 1target Cytochrome P450 3A4enzyme Cytochrome P450 3A5enzyme UDP-glucuronosyltransferase 1A1enzyme UDP-glucuronosyltransferase 1A9enzyme Cytochrome P450 3A7enzyme Solute carrier family 22 member 3transporter Solute carrier organic anion transporter family member 1B1transporter Multidrug resistance-associated protein 1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Albumincarrier ATP-dependent translocase ABCB1transporter ATP-binding cassette sub-family C member 2transporter Human Carboxylesterasesenzyme
Pembrolizumab	A PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma.	Programmed cell death protein 1target Programmed cell death 1 ligand 1target
Pemetrexed	A folate analog used to treat mesothelioma and non-small cell lung cancer.	Thymidylate synthasetarget Dihydrofolate reductasetarget Trifunctional purine biosynthetic protein adenosine-3target Deoxycytidine kinaseenzyme Bifunctional purine biosynthesis protein ATICtarget Equilibrative nucleoside transporter 1enzyme Organic anion transporter 3transporter Reduced folate transportertransporter Proton-coupled folate transportertransporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter ATP-binding cassette sub-family C member 5transporter Solute carrier family 22 member 6transporter Albumincarrier Solute carrier family 22 member 11transporter Thymidylate synthasetarget
Tisotumab vedotin	A tissue factor-directed antibody drug conjugate that is used to treat adults with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.	Cytochrome P450 3A4enzyme Tissue factortarget ATP-dependent translocase ABCB1transporter
Vinorelbine	A vinca alkaloid used in the treatment of metastatic non-small cell lung carcinoma (NSLC) and in conjunction with other drugs in locally advanced NSCLC.	Tubulin beta chaintarget Cytochrome P450 3A4enzyme Cytochrome P450 2D6enzyme

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT06313268	Safety of Effivia®, a Bevacizumab Biosimilar	Bevacizumab	Not Available	Not Available	completed
NCT04266886	Self-Hypnosis for the Enhanced Recovery After Surgery in Patients with Gynecologic Cancer	No drug interventions	supportive_care	Not Available	active_not_recruiting
NCT04865887	Pembrolizumab and Lenvatinib in Advanced Cervical Cancer	Lenvatinib Pembrolizumab	treatment	2	recruiting
NCT06157151	PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer	Pembrolizumab	treatment	2	recruiting
NCT05614453	Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based Chemotherapy	Sitravatinib Tislelizumab	treatment	2	withdrawn
NCT04380805	A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer	Cadonilimab	treatment	2	completed
NCT05446883	QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer	Carboplatin Cisplatin Paclitaxel QL1706	treatment	3	recruiting
NCT00532818	Hydralazine Valproate for Cervical Cancer	Hydralazine Valproic acid	treatment	3	unknown_status
NCT04943627	Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)	Balstilimab Gemcitabine Irinotecan Pemetrexed Topotecan Vinorelbine	treatment	3	withdrawn
NCT00430781	Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer	Lapatinib Pazopanib	treatment	2	completed
NCT04230954	Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer	Cabozantinib Pembrolizumab	treatment	2	terminated
NCT03816553	SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer	Camrelizumab Rivoceranib	treatment	2	completed
NCT03786107	HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib	No drug interventions	Not Available	Not Available	terminated
NCT06238635	Dostarlimab and Cobolimab in Advanced Cervical Cancer	Cobolimab Dostarlimab	treatment	2	recruiting
NCT03277482	Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer	Durvalumab Tremelimumab	treatment	1	terminated
NCT03912402	Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer (CAESURA)	Bevacizumab Carboplatin Cisplatin Paclitaxel	treatment	2	unknown_status
NCT03614949	SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer	Atezolizumab	treatment	2	recruiting